Search the Newsreel

Maze Therapeutics Inc (MAZE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

BlackRock Inc. (MAZE) reports 5.4% beneficial ownership in Maze Therapeutics

BlackRock, Inc. has disclosed a passive beneficial ownership of 5.4% in Maze Therapeutics Inc. common stock, amounting to 2,978,114 shares. The firm has sole voting power over 2,922,889 shares and sole dispositive power over all 2,978,114 shares, with no shared powers. This information was …

MAZE (NASDAQ: MAZE) investor plans 22,500-share sale after option exercise

Atul Dandekar, a shareholder of Maze Therapeutics, Inc. (NASDAQ: MAZE), has filed to sell up to 22,500 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. This planned transaction, with an anticipated date of July 29, 2026, follows an exercise …

Maze Therapeutics Inc (MAZE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Maze Therapeutics Inc (MAZE), detailing its current price momentum, support and resistance levels, and the readings from various technical indicators and moving averages. The company's stock shows a current price momentum score of 4.20, trading between resistance …

Maze Therapeutics Inc (MAZE) Institutional Confidence

Maze Therapeutics Inc (MAZE) has achieved an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion has increased by 14.80% quarter-over-quarter to 97.33%. James Simons is the largest institutional shareholder, with other significant …

Spruce Street Capital LP Makes New $5.97 Million Investment in Maze Therapeutics, Inc. $MAZE

Maze Therapeutics Inc (MAZE) Cash Flow

This article provides a detailed cash flow statement for Maze Therapeutics Inc (MAZE), including operating, investing, and financing cash flows presented quarterly and annually. It also offers definitions and explanations for key cash flow metrics like operating cash flow, investing cash flow, financing cash …

MAZE|Maze Therapeutics Inc|Price:27.680|

This article provides a comprehensive stock analysis of Maze Therapeutics Inc (MAZE) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company has strong fundamentals, high growth potential, and is considered fairly valued within …

Maze Therapeutics Inc (MAZE) Valuation: PE, PB & Fair Value Analysis

Maze Therapeutics Inc (MAZE) has a current valuation score of 8.80, placing it 92nd out of 386 companies in the Biotechnology & Medical Research industry. Its P/E ratio stands at -11.75, which is significantly below its recent high and above its recent low. However, …

Maze Therapeutics, Inc. Revenue Breakdown – NASDAQ:MAZE

This article provides a revenue breakdown for Maze Therapeutics, Inc. (NASDAQ: MAZE) as found on TradingView. It offers an overview of the company's financial data, including statements, statistics, dividends, earnings, and segment information, categorized by source and country. The content directs users to further …

Maze Therapeutics Inc (MAZE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Maze Therapeutics Inc (MAZE), listing its major shareholders and institutional holdings. It breaks down shareholders by type, including venture capital, hedge funds, and investment advisors, and also provides a historical overview of institutional shareholding data and related …

Maze Therapeutics (MAZE) Q4 2025 earnings summary

Maze Therapeutics reported its Q4 and full-year 2025 earnings, highlighting positive Phase 2 HORIZON trial data for MZE829 in AMKD and plans for two Phase 2 trials for MZE782 in 2026. The company achieved a $20 million milestone for MZE001 and ended the year …

Maze Therapeutics (MAZE) Investor presentation Summary

Maze Therapeutics is focused on developing precision medicines for kidney and metabolic diseases, with a cash runway extending into 2029. Their lead programs, MZE829 for APOL1-mediated kidney disease (AMKD) and MZE782 for phenylketonuria (PKU) and chronic kidney disease (CKD), have shown promising clinical results. …

3 Valuation Signals For Maze Therapeutics (MAZE) As Shares Close At $29.30

Maze Therapeutics (MAZE) shares closed at $29.30, experiencing mixed returns recently but showing significant year-on-year growth despite a year-to-date decline. The company's valuation, based on a Price-to-Book (P/B) ratio of 4.7x, appears to be about right compared to its peers and the broader US …

Maze Therapeutics (MAZE) Stock Looks Fully Priced After A 59% Gain##

Maze Therapeutics (MAZE) has seen a significant 59.2% stock return over the past year, but a low value score and overvalued market multiples suggest the stock is fully priced. The company's P/B ratio of 4.4x is substantially higher than the industry average of 2.4x, …